WO2002072830A3 - Proteines associees a la croissance, a la differenciation et a la mort cellulaire - Google Patents

Proteines associees a la croissance, a la differenciation et a la mort cellulaire Download PDF

Info

Publication number
WO2002072830A3
WO2002072830A3 PCT/US2002/003715 US0203715W WO02072830A3 WO 2002072830 A3 WO2002072830 A3 WO 2002072830A3 US 0203715 W US0203715 W US 0203715W WO 02072830 A3 WO02072830 A3 WO 02072830A3
Authority
WO
WIPO (PCT)
Prior art keywords
death
differentiation
cell growth
proteins associated
cgdd
Prior art date
Application number
PCT/US2002/003715
Other languages
English (en)
Other versions
WO2002072830A2 (fr
Inventor
Henry Yue
Monique G Yao
Craig H Ison
Yan Lu
Bridget A Warren
Vicki S Elliott
Mariah R Baughn
Li Ding
Yuming Xu
Kimberly J Gietzen
Tom Y Tang
Preeti G Lal
Brendan M Duggan
Neil Burford
Dyung Aina M Lu
Thomas W Richardson
Uyen K Tran
Reena Khare
Narinder K Chawla
Original Assignee
Incyte Genomics Inc
Henry Yue
Monique G Yao
Craig H Ison
Yan Lu
Bridget A Warren
Vicki S Elliott
Mariah R Baughn
Li Ding
Yuming Xu
Kimberly J Gietzen
Tom Y Tang
Preeti G Lal
Brendan M Duggan
Neil Burford
Dyung Aina M Lu
Thomas W Richardson
Uyen K Tran
Reena Khare
Narinder K Chawla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Henry Yue, Monique G Yao, Craig H Ison, Yan Lu, Bridget A Warren, Vicki S Elliott, Mariah R Baughn, Li Ding, Yuming Xu, Kimberly J Gietzen, Tom Y Tang, Preeti G Lal, Brendan M Duggan, Neil Burford, Dyung Aina M Lu, Thomas W Richardson, Uyen K Tran, Reena Khare, Narinder K Chawla filed Critical Incyte Genomics Inc
Priority to EP02703358A priority Critical patent/EP1358326A2/fr
Priority to AU2002236984A priority patent/AU2002236984A1/en
Priority to US10/467,535 priority patent/US20040146970A1/en
Priority to JP2002571884A priority patent/JP2004521627A/ja
Priority to CA002441495A priority patent/CA2441495A1/fr
Publication of WO2002072830A2 publication Critical patent/WO2002072830A2/fr
Publication of WO2002072830A3 publication Critical patent/WO2002072830A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)

Abstract

L'invention concerne des protéines humaines associées à la croissance, à la différenciation et à la mort cellulaire (CGDD) et des polynucléotides permettant d'identifier et de coder ces protéines CGDD. L'invention concerne également des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. L'invention concerne également des méthodes destinées au diagnostic, au traitement ou à la prévention de troubles associés à l'expression aberrante de ces protéines CGDD.
PCT/US2002/003715 2001-02-09 2002-02-08 Proteines associees a la croissance, a la differenciation et a la mort cellulaire WO2002072830A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP02703358A EP1358326A2 (fr) 2001-02-09 2002-02-08 Proteines associees a la croissance, a la differenciation et a la mort cellulaire
AU2002236984A AU2002236984A1 (en) 2001-02-09 2002-02-08 Proteins associated with cell growth, differentiation, and death
US10/467,535 US20040146970A1 (en) 2002-02-08 2002-02-08 Proteins associated with cell growth, differentiation, and death
JP2002571884A JP2004521627A (ja) 2001-02-09 2002-02-08 細胞増殖、細胞分化および細胞死に関連するタンパク質
CA002441495A CA2441495A1 (fr) 2001-02-09 2002-02-08 Proteines associees a la croissance, a la differenciation et a la mort cellulaire

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26811101P 2001-02-09 2001-02-09
US60/268,111 2001-02-09
US27117501P 2001-02-23 2001-02-23
US60/271,175 2001-02-23
US27450301P 2001-03-08 2001-03-08
US60/274,503 2001-03-08
US27455201P 2001-03-09 2001-03-09
US60/274,552 2001-03-09

Publications (2)

Publication Number Publication Date
WO2002072830A2 WO2002072830A2 (fr) 2002-09-19
WO2002072830A3 true WO2002072830A3 (fr) 2003-09-12

Family

ID=27500926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003715 WO2002072830A2 (fr) 2001-02-09 2002-02-08 Proteines associees a la croissance, a la differenciation et a la mort cellulaire

Country Status (5)

Country Link
EP (1) EP1358326A2 (fr)
JP (1) JP2004521627A (fr)
AU (1) AU2002236984A1 (fr)
CA (1) CA2441495A1 (fr)
WO (1) WO2002072830A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002055704A2 (fr) * 2001-01-09 2002-07-18 Curagen Corp Proteines, polynucleotides codant pour elles et procedes d'utilisation correspondants
US6962811B2 (en) 2001-05-09 2005-11-08 Millennium Pharmaceuticals, Inc. 14715, a human fringe family member nucleic acids and uses therefor
US7074576B2 (en) * 2001-11-23 2006-07-11 Syn X Pharma, Inc. Protein biopolymer markers indicative of alzheimer's disease
WO2005024428A1 (fr) * 2003-09-08 2005-03-17 Cellfree Sciences Co., Ltd. Nouveau procede de criblage a haut rendement d'un medicament pour une proteine active sur le plan physiologique
AU2006291990B2 (en) 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
WO2013123588A1 (fr) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Utilisation conjointe d'un inhibiteur de clusterine et d'un inhibiteur d'egfr pour traiter le cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A2 (fr) * 1999-07-29 2001-02-07 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation
CN1292385A (zh) * 1999-10-10 2001-04-25 上海博道基因技术有限公司 一种新的多肽——人dna－pk相互作用蛋白75和编码这种多肽的多核苷酸
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1074617A2 (fr) * 1999-07-29 2001-02-07 Helix Research Institute Amorces pour la synthèse de cADN de pleine longueur et leur utilisation
CN1292385A (zh) * 1999-10-10 2001-04-25 上海博道基因技术有限公司 一种新的多肽——人dna－pk相互作用蛋白75和编码这种多肽的多核苷酸
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 22 February 2000 (2000-02-22), XP002228549, retrieved from EBI Database accession no. AK002205 *
DATABASE EMBL [online] 22 October 2001 (2001-10-22), HYSEC INC, XP002228556, retrieved from EBI Database accession no. AAI58717 *
DATABASE EMBL [online] 26 February 2001 (2001-02-26), XP002228567, retrieved from EBI Database accession no. AAB93699 *
DATABASE EMBL [online] 26 June 2001 (2001-06-26), XP002228568, retrieved from EBI Database accession no. AAH15185 *
DATABASE EMBL [online] 27 August 2002 (2002-08-27), MAO Y , AND XIE Y, XP002228555, retrieved from EBI Database accession no. ABB08943 *
DATABASE EMBL [online] 27 August 2002 (2002-08-27), XP002228573, retrieved from EBI Database accession no. ABL41474 *
DATABASE EMBL [online] 28 June 2000 (2000-06-28), XP002228553, retrieved from EBI Database accession no. HSM802748 *
DATABASE EMBL [online] 6 March 2000 (2000-03-06), STRENNER-LIEWEN ET AL.: "Homo sapiens tumor antigen SLP-8p", XP002228546, retrieved from EBI Database accession no. AF102177 *
DATABASE SWALL [online] 1 October 2000 (2000-10-01), ISOGAI T. ET AL., XP002228548, retrieved from EBI Database accession no. Q9NUJ0 *
DATABASE SWALL [online] 1 October 2000 (2000-10-01), OTTENWAELDER B. ET AL., XP002228552, retrieved from EBI Database accession no. Q9NPV0 *
DATABASE SWALL [online] 1 October 2000 (2000-10-01), STARK S ET AL., XP002228554, retrieved from EBI Database accession no. Q9JMK8 *
SHIUE L: "IDENTIFICATION OF CANDIDATE GENES FOR DRUG DISCOVERY BY DIFFERENTIAL DISPLAY", DRUG DEVELOPMENT RESEARCH, NEW YORK, NY, US, vol. 41, 1997, pages 142 - 159, XP000893087, ISSN: 0272-4391 *
SONNHAMMER E L L ET AL: "PFAM: A COMPREHENSIVE DATABASE OF PROTEIN DOMAIN FAMILIES BASED ON SEED ALIGNMENTS", PROTEINS: STRUCTURE, FUNCTION AND GENETICS, ALAN R. LISS, US, vol. 28, 1997, pages 405 - 420, XP002929239, ISSN: 0887-3585 *

Also Published As

Publication number Publication date
CA2441495A1 (fr) 2002-09-19
WO2002072830A2 (fr) 2002-09-19
AU2002236984A1 (en) 2002-09-24
EP1358326A2 (fr) 2003-11-05
JP2004521627A (ja) 2004-07-22

Similar Documents

Publication Publication Date Title
WO2001012662A3 (fr) Proteines associees a la membrane
WO2003008553A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort cellulaires
WO2003014322A3 (fr) Proteines associees a la croissance, la differentiation et la mort cellulaires
WO2001020004A3 (fr) Proteines phosphatase et proteines kinase
WO2002097060A3 (fr) Proteines associees aux carbohydrates
WO2001096546A3 (fr) Proteine-phosphatases
WO2003077875A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort cellulaires
WO2002072830A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort cellulaire
WO2001085942A3 (fr) Proteines associees au cytosquelette
WO2002010363A3 (fr) Proteines phosphatases
WO2002097032A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort cellulaire
WO2002102310A3 (fr) Proteines associees a la croissance, la differenciation et la mort de cellules
WO2002053719A3 (fr) Proteines associees au cytosquelette
WO2000008155A3 (fr) Proteines associees a un recepteur humain
WO2004031364A3 (fr) Proteines associees a la croissance, a la differenciation, et a la mort des cellules
WO2002066646A3 (fr) Proteines associees a la neurotransmission
WO2003027263A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort des cellules
WO2003095622A3 (fr) Proteines associees a la croissance, la differentiation et la mort cellulaires
WO2001094391A3 (fr) Proteines de signalisation intracellulaires
WO2003025542A3 (fr) Proteines associees a la reponse immunitaire
WO2002048368A3 (fr) Proteines associees a la croissance, a la differenciation et a la mort cellulaire
WO2003050253A3 (fr) Proteines associees a la croissance, differentiation et mort cellulaires
WO2002088322A3 (fr) Proteines d'adhesion cellulaire et proteines de matrice extracellulaire
WO2002016587A3 (fr) Proteines associees aux microtubules et tubulines
WO2000071679A3 (fr) Proteines d'oxydoreductase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2441495

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002571884

Country of ref document: JP

Ref document number: 10467535

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002703358

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002703358

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002703358

Country of ref document: EP